Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pediatric Oncology

Pediatric ALCL: A Guide for Parents

At a Glance

Pediatric Anaplastic Large Cell Lymphoma (ALCL) is a highly curable cancer, with 70% to 90% of children achieving long-term survival. Treatment typically relies on intensive, specialized chemotherapy protocols, and doctors use MDD testing to tailor the approach to your child's specific risk level.

Hearing that your child has Anaplastic Large Cell Lymphoma (ALCL) is a moment of profound shock. However, it is important to know that pediatric ALCL is a highly curable disease [1]. Children’s bodies often respond very differently to treatment than adults, and pediatric oncology has developed specialized, highly successful protocols specifically for them [2][3].

A Note on Fertility Preservation

Because standard multi-agent chemotherapy regimens can sometimes impact future fertility, discussing fertility preservation options with your pediatric oncologist is a critical step before beginning treatment.

The Standard of Care: Multi-Agent Chemotherapy

Most children with ALCL are treated with a combination of several different chemotherapy drugs. The most common “blueprint” for this is a protocol known as ALCL99 [4].

  • How it Works: This regimen uses short, intensive cycles of chemotherapy delivered every few weeks [3]. It is designed to hit the cancer hard and fast while allowing your child’s healthy cells time to recover between cycles.
  • Success Rates: With these standard protocols, approximately 70% to 90% of children achieve long-term survival [5][6].
  • Modern Additions: Newer trials (like ANHL12P1) have successfully added a targeted drug called brentuximab vedotin (BV) to the standard chemotherapy mix [1][7]. This combination has been shown to be very effective at preventing relapses during therapy without adding significant extra toxicity [7][3].

Understanding “Minimal Disseminated Disease” (MDD)

One of the most important tools pediatric doctors use is called Minimal Disseminated Disease (MDD) testing [8].

  • The Concept: Even if a scan (like a PET or CT) looks clear, there may be a tiny number of lymphoma cells hidden in the bone marrow or blood that are invisible to the naked eye [8][9].
  • The Test: Doctors use a highly sensitive molecular test (like RT-PCR) to search for a specific genetic “signature” called the NPM-ALK transcript [8][10].
  • Why it Matters: MDD status helps doctors “risk-stratify” your child [11]. If MDD is present at diagnosis, your child might be considered “higher risk,” and the doctors may adjust the intensity of the treatment to ensure the best possible outcome [12][13]. Targeted therapies like BV are often reserved for patients identified as “high risk,” making MDD status incredibly important.

Targeted Therapies and Relapse

If the lymphoma does not respond to initial treatment or returns later, doctors have powerful “targeted” second-line defenses [14].

ALK Inhibitors (Crizotinib)

Because almost all pediatric ALCL cases are ALK-positive, they have a specific “broken switch” that fuels the cancer [15]. Drugs called ALK inhibitors, such as crizotinib, are designed to specifically turn that switch off [16].

  • Crizotinib is often taken as a pill and has shown remarkable success in achieving complete remissions in children whose cancer has returned [17][18].
  • It is also uniquely useful because it can reach the Central Nervous System (CNS), helping to treat rare cases where the lymphoma has moved into the brain or spinal fluid [17][19].

Looking Ahead

While the journey through treatment is challenging, the goal for pediatric ALCL is almost always a permanent cure [1]. Your child’s medical team will use a combination of intensive chemotherapy, advanced molecular monitoring (MDD), and targeted therapies to provide the most effective care possible while protecting your child’s long-term health [10][7].

Return to Home

Common questions in this guide

What is the success rate for treating pediatric ALCL?
Pediatric ALCL is considered a highly curable disease. With standard multi-agent chemotherapy regimens, approximately 70% to 90% of children achieve long-term survival.
What is Minimal Disseminated Disease (MDD) testing?
Minimal Disseminated Disease refers to tiny amounts of lymphoma cells hidden in the blood or bone marrow that cannot be seen on standard imaging scans. Doctors use a highly sensitive test to find these cells, which helps them determine the best treatment intensity for your child.
Will ALCL treatment affect my child's future fertility?
Standard multi-agent chemotherapy regimens used for ALCL can sometimes impact a child's future fertility. It is very important for parents to discuss fertility preservation options with the pediatric oncologist before starting any treatments.
What happens if my child's ALCL comes back after initial chemotherapy?
If the lymphoma does not respond or returns, doctors can use targeted therapies called ALK inhibitors, such as crizotinib. These oral medications specifically target the genetic mutation driving the cancer and have shown remarkable success in achieving remission.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my child's Minimal Disseminated Disease (MDD) status, and how does it affect their risk category?
  2. 2.Is our treatment plan based on the ALCL99 protocol or the newer ANHL12P1 protocol that includes brentuximab vedotin?
  3. 3.How often will you be monitoring for Minimal Residual Disease (MRD) during and after treatment?
  4. 4.If my child's lymphoma is high-risk, will we be using brentuximab vedotin as part of the initial therapy?
  5. 5.In the event that the cancer returns, what is the protocol for using ALK inhibitors like crizotinib?
  6. 6.Are there fertility preservation options we should explore for my child before chemotherapy begins?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.

    Lowe EJ, Reilly AF, Lim MS, et al.

    Blood 2021; (137(26)):3595-3603 doi:10.1182/blood.2020009806.

    PMID: 33684925
  2. 2

    Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma.

    Khanlari M, Li S, Miranda RN, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022; (35(3)):412-418 doi:10.1038/s41379-021-00944-1.

    PMID: 34628481
  3. 3

    Advances and updates in pediatric anaplastic large cell lymphoma.

    Marks LJ, Lowe E, Kamdar K

    Blood advances 2025; (9(19)):4870-4880 doi:10.1182/bloodadvances.2025015935.

    PMID: 40690755
  4. 4

    Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis.

    Kanazawa Y, Yamashita Y, Fujiwara M, et al.

    Acta medica Okayama 2016; (70(6)):503-506 doi:10.18926/AMO/54815.

    PMID: 28003677
  5. 5

    Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes.

    Hudson S, Wang D, Middleton F, et al.

    Pediatric blood & cancer 2018; (65(8)):e27094 doi:10.1002/pbc.27094.

    PMID: 29697184
  6. 6

    Clinical profile and outcome of children with anaplastic large cell lymphoma treated with short-course chemotherapy - ten years experience from a tertiary care center in a LMIC.

    Trivedi M, Thankamony P, Nair M, et al.

    Pediatric hematology and oncology 2023; (40(5)):485-496 doi:10.1080/08880018.2023.2212710.

    PMID: 37477212
  7. 7

    Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.

    Agrusa JE, Egress ER, Lowe EJ

    Frontiers in immunology 2023; (14()):1203471 doi:10.3389/fimmu.2023.1203471.

    PMID: 37275877
  8. 8

    Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma.

    Damm-Welk C, Kutscher N, Zimmermann M, et al.

    Haematologica 2020; (105(8)):2141-2149 doi:10.3324/haematol.2019.232314.

    PMID: 31649129
  9. 9

    Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges.

    Mussolin L, Damm-Welk C, Pillon M, Woessmann W

    Cancers 2021; (13(8)) doi:10.3390/cancers13081907.

    PMID: 33921029
  10. 10

    Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?

    Rigaud C, Abbas R, Grand D, et al.

    Pediatric blood & cancer 2021; (68(6)):e28982 doi:10.1002/pbc.28982.

    PMID: 33687135
  11. 11

    Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma.

    Iijima-Yamashita Y, Mori T, Nakazawa A, et al.

    International journal of hematology 2018; (107(2)):244-250 doi:10.1007/s12185-017-2338-6.

    PMID: 29030834
  12. 12

    Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.

    Lowe EJ, Reilly AF, Lim MS, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(11)):2043-2053 doi:10.1200/JCO.22.00272.

    PMID: 36534942
  13. 13

    Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience.

    Lovisa F, Gallingani I, Varotto E, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(9)) doi:10.3390/diagnostics11091594.

    PMID: 34573936
  14. 14

    Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

    Locatelli F, Mauz-Koerholz C, Neville K, et al.

    The Lancet. Haematology 2018; (5(10)):e450-e461 doi:10.1016/S2352-3026(18)30153-4.

    PMID: 30290902
  15. 15

    Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.

    Blombery P, Thompson ER, Jones K, et al.

    Haematologica 2016; (101(9)):e387-90 doi:10.3324/haematol.2016.146118.

    PMID: 27198716
  16. 16

    Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent.

    Shang C, Hassan B, Haque M, et al.

    Cancers 2021; (13(2)) doi:10.3390/cancers13020181.

    PMID: 33430343
  17. 17

    Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.

    Shen D, Song H, Zhang J, et al.

    Journal of pediatric hematology/oncology 2022; (44(1)):e1-e4 doi:10.1097/MPH.0000000000002137.

    PMID: 33661174
  18. 18

    Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.

    Torossian A, Broin N, Frentzel J, et al.

    Haematologica 2019; (104(7)):1428-1439 doi:10.3324/haematol.2017.181966.

    PMID: 30679328
  19. 19

    Primary Leptomeningeal Lymphoma: Clinicopathologic Features of 2 Rare Phenotypes.

    Vizcaino MA, Giannini C, King RL, et al.

    Journal of neuropathology and experimental neurology 2022; (81(12)):1002-1007 doi:10.1093/jnen/nlac084.

    PMID: 36102830

This guide is for educational purposes to help parents understand pediatric ALCL treatments. Always consult your pediatric oncologist for medical advice tailored to your child's specific diagnosis.

Get notified when new evidence is published on Anaplastic large cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.